David Jarrard

12PUBLICATIONS
33CO-AUTHORS
Molecular targetsOther philosophy and religious studies not elsewhere classifiedMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jan 13, 2026
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer.

Surendra Gulla, Tej Sharma, Ephraim Gardner

|Jan 08, 2026
Response to comment by Semwal et al.

Arighno Das, David Jarrard

|Nov 05, 2025
Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.

Arighno Das, Marcelo Bigarella, Krista Brackman

|Aug 18, 2022
Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.

Mikolaj J Filon, Amani A Gillette, Bing Yang

|May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.

Alicia K Morgans, Yu-Hui Chen, David F Jarrard

|Feb 28, 2022
Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment.

Ross A Vitek, Wei Huang, Peter G Geiger

Pageof 2

Frequent Collaborators

1 joint publications

Ross A Vitek

1 joint publications

Wei Huang

1 joint publications

Erika Heninger

1 joint publications

Joshua M Lang